Van Gogh^TM

15-20% of cancer is missed due to several factors including the technical limitations of pathological processes and manpower constraints. Current techniques for tissue evaluation take time, can damage the biopsy, and can provide widely variable results. This can prolong procedures and increase the need for additional biopsies. These setbacks can delay diagnoses, potentially miss cancer and impact patient treatment timelines. CellTivity Scientific’s Van GoghTM addresses these challenges.

Powered by Dynamic Cell Imaging (DCI), Van Gogh can analyze any biopsy at a depth of 150μm below the tissue surface and measure intracellular and metabolic activity throughout. This process does not require any cutting or staining, leaving the sample unchanged for final pathology to accurately diagnose and perform next-generation sequencing (NGS). Using light, the cell shape, size, and activity are highlighted in a heatmap, making it easier to assess tissue adequacy.

Intended use: An FDA Class I in-vitro diagnostic medical device.

The Van Gogh system uses a specialized phase contrast microscope that employs an advanced form of Michelson interferometry to target appropriate tissue and capture metabolic activity of individual cells. This proprietary technology, known as Dynamic Cell Imaging (DCI), overlays metabolic activity onto a traditional morphological assessment, enhances the cellular contrast by capturing the residual microscopic intracellular movements in freshly excised tissue and distinguishes them from normal alveolar-parenchymal tissue.

This contrast is displayed in the form of a heatmap, allowing the sampled abnormality to be distinctive from any surrounding normal tissue. Finally, standard morphologic characteristics support the reader in identifying cellular features representative of malignant or non-malignant, inflammatory disease, or other benign lesions can be recognized.